Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Full Year Results “We delivered another year of double-digit organic sales growth ...

“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, ...

Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York ...

Regarding its outlook, Stryker logged expects organic sales growth of 8% to 9% for 2025, and adjusted earnings of $13.45 to $13.70 a share, as it sees sustained levels of procedural volumes and strong ...

Stryker plans to sell its U.S. spinal implants business, the company said Jan. 28. The U.S. spine segment will be sold to investment firm Viscogliosi Brothers, and that group will create VB Spine, ...

Stryker stock dipped late Tuesday after the medtech company beat forecasts, but announced its plan to divest the U.S. spinal ...